Ref. No.P-66/2026-27/27
August 13, 2026

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Dear Sir/Madam,

Please find the enclosed herewith Investor's Presentation / Company Update of Agrochemicals and Diagnostic Kits (Health Care) for your information and necessary action.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

NIKHILKUBER DUBEY

Digitally signed by NIKHILKUBER DUBEY
Date: 2026.08.13 16:19:43 +05'30'

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: As above

3B BlackBio Dx Ltd.

Since 1972

Investor Presentation

August, 2026

Disclaimer

This presentation and the accompanying slides (the "Presentation"), which has been prepared by 3B BlackBio Dx Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Financial Highlights – Consolidated – Q1 2026-27



Consolidated (In ₹ Lakhs)	Q1 2025-26	Q1 2026-27
Revenue from Operations	2,223.46	3,349.08
Profit Before Tax	1,586.35	1,321.95
Profit After Tax	1,264.45	897.84
Paid-Up Equity Share Capital	856.84	856.84
Reserves	26,243.65	26,243.65
EPS	14.76	10.48

***In above numbers, CORIS sales of ₹862.83 Lakh is included**

***** In above numbers, CORIS negative EBITDA of ₹(352.24) Lakh is included**

Last Year Q1 figures do not include Coris numbers as the date of consolidation was 29th August 2025.

Financial Highlights – Consolidated excl. Coris – Q1 2026-27



Consolidated (in ₹ Lakhs)	Q1 2025-26	Q1 2026-27
Revenue from Operations	₹2,223.46	₹2,486.24
Profit Before Tax	1,586.35	1,791.76
Profit After Tax	1,264.45	1,367.66
Paid-Up Equity Share Capital	856.84	856.84
Reserves	26,243.65	32,307.03
EPS	14.76	15.96

In above numbers, CORIS figures are not included.

Key Highlights – Agrochemicals Division

Main Thrust Area of R&D

- Development of novel formulations for agriculture and public health which are less harmful and cost effective.
- Performance monitoring of existing products/process.
- Improvement in existing products/process with a customer driven approach.

Future Outlook of Agro-Chemical Division

The Agro-Chemical division maintains focus to government procurement, primarily facilitated through electronic tenders on platforms such as GeM, and exports to Bangladesh mainly. Presently, the Agro business operates with minimal debt. Sales within the agrochemical sector remain stable, with vision to only supply to old customers, Govt. tenders for Vector borne disease control & exports.

Agrochemicals Exports

The export sales of our agrochemicals division amounted to INR 58.99 Lakh in Q1 2026-27 compared to INR 53.58 Lakh in Q1 2025-26.

Agrochemicals - Existing Products

Chemicals	No. of Products	Biologicals	No. of Products
Insecticides	70	Bio pesticide	07
Antibacterials	01	Bio fungicide	01
Fungicides	15	Bio fertilizers	05
Herbicides	11	Bio nematicides	01
Public Health	11	Public Health	02
Microfertilizers	02	Health & Hygiene	06
Chelated Zinc	01	Repellents	03
Plant Growth Regulators	02		

Kilpest

ISO 9001 QUALITY ASSURANCE

3B BlackBio has been selected as a part of “**Select 200 Companies**” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist.

3B BlackBio Dx Ltd.
GROUP

UNITED KINGDOM

INDIA

BELGIUM

Financial Highlights:

Molecular Diagnostics

(MDx) Division

Q1 2026-27

Overview – MDx Division

- **Founded**: November 2010 | **15 years** in molecular diagnostics
- **Core Focus**: Design, Development & Manufacture of Molecular Diagnostic Kits:
  - qPCR Assays (TRUPCR®)
  - Lateral Flow Assays (TRURAPID®)
  - NGS Assays (TRUNGS®)
  - Digital PCR Assays (TRUdPCR®)
- **Product Portfolio**: 120+ Molecular Diagnostic Assays Developed
- **Certifications**:
  - ✓ ISO 13485:2016 (BSI, UK)
  - ✓ Licensed by CDSCO, Govt. of India
  - ✓ IVDR compliant (EU 2017/746)
- **Awards & Recognition**:
  - *National MSME Award 2018* (Presented by Hon. President of India)
  - *Outstanding Achievement Award* (2017 & 2022) – MP Chambers of Commerce & Industries
  - Featured in **FORBES INDIA DGEMS 2023** – Top 200 Global Potential Companies

TRUPCR®

TRUPCR® EUROPE

Overview – MDx Division

Well Established Brand

Well established molecular diagnostics (MDx) brand with largest range of Indian IVD and CE-IVD Products available

PAN-India & Global Presence

Product & customer support access available to over 1,000 labs / hospitals in India across 100+ cities in India and 70+ countries internationally

Comprehensive Molecular Diagnostics

Only company to have qPCR Assays, Lateral Flow Tests and NGS assays available together, providing the most comprehensive molecular diagnostics solutions to customers

TRUPCR®

TRUPCR® EUROPE

JOURNEY AT A GLANCE

1

2011-2013

- Founded as a Lifesciences company
- Initiated R&D in Molecular Diagnostics

2

2014–2016

- Entry into Molecular Diagnostics with Launch of TRUPCR® MDx Kits in Infectious Diseases & Oncology Portfolio

3

2017-2018

- Received FMPCCI Outstanding Achievement Award
- Received National MSME Award by Honorable President of INDIA

4

2019-2020

- ICMR Approval & USFDA - EUA for COVID PCR Test
- Started International Expansion

5

2021

- Launch of TRURAPID® Vertical with assays based on Lateral Flow
- Launch of TRUPCR® Europe Limited, United Kingdom

6

2022

- Received ISO 13485:2016 Accreditation from BSI, UK
- Received FMPCCI Outstanding Achievement Award for the second time

7

2023

- Launch of AMR Kits in TRURAPID®
- Became Part of Forbes India Select 200 companies with global potential
- Scheme of Amalgamation Implemented - Company Name Changed - 3B BlackBio Dx Ltd.

8

2024

- Commercial Launch of TRUNGS® Assays

9

2025

- Acquisition of Coris BioConcept SRL, Belgium

Our Strategic Priorities

Market Penetration:

We aim to boost sales with current customers and channel partners by expanding the range of products within their existing portfolios.

Portfolio Expansion:

Leveraging our R&D strengths, we continuously evolve our portfolio – with new assays in qPCR, Lateral flow immunoassay, NGS.

Geographical Reach:

We are entering untapped regions through strategic partnerships with local distributors and direct engagement In emerging markets.

Mergers & Acquisitions:

In view of our long-term growth strategy, we are pursuing strategic M&A opportunities. Our objective is to maximize value for our stakeholders.

TRUPCR®

TRUPCR® EUROPE

MDx Growth Canvas excluding Coris



	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Sales in Millions INR	76.5	111.9	153.6	2,142.1	668.3	505.2	608.5	842.8	952.1
No. of customers	100	152	180	800	400	400	600	700	900+

MDx Growth Canvas including Coris



	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Sales in Millions INR	76.5	111.9	153.6	2,142.1	668.3	505.2	608.5	842.8	1,311.2
No. of customers	100	152	180	800	400	400	600	700	1,000+

Dx Business – Financials Highlights – Q1 2026-27



Revenue from Operations



EBITDA



PBT



PAT

In ₹ Lakhs

* In above numbers, CORIS sales of ₹862.83 Lakh is included.

** In above numbers, CORIS negative EBITDA of ₹(352.24) Lakh is included.

TRUPCR®

CORIS BioConcept

TRUPCR® EUROPE

MDx Business – Financials Highlights excl. Coris Q1 2026-27









In above numbers, CORIS figures are not included.

In ₹ Lakhs

Business Outlook – MDx (2026-27)

Market Overview & Growth Outlook

- The **Total Addressable Market (TAM)** for Molecular Diagnostics (MDx) in India is estimated at approx. **₹500–600 Cr**.
- We hold approximately **15% market share**, positioning us among the **market leaders**.
- The MDx industry is projected to grow at **8%–10% CAGR** over the next few years in India due to increasing adoption across diagnostic labs and hospitals and government projects.
- While this growth is attracting increased competition, we are hoping to grow at **15%–20% overall taking both domestic and export sales** for **FY 2026–27**, backed by our extensive product portfolio and strong market presence over the years and high-quality products well accepted by the customers. However, the geo political tensions is affecting the sales as of now but we hope that we can maintain the growth with extensive efforts.
- The launch of unique panels will expand our market reach, capture high-growth segments, and drive sustained growth.
- Increasing ageing population in India, life style changes, evidence based treatments and better access to healthcare, will play a major role in our growth.

Business Outlook – Dx (Q1 2026-27)

We closed Q1 2026-27 with revenue from operations of ₹3,205.73 Lakh compared to ₹1,996.06 Lakh in Q1 2025-26. This includes consolidated sales from TRUPCR Europe Limited, Manchester of ₹ 542.91 Lakh and sales from Coris BioConcept SRL, Belgium of ₹862.83 Lakh. In Q1 2026-27, we did export of ₹596.28 Lakh against ₹430.90 Lakh in Q1 2025-26.



Q1 2026-27 for 3B Standalone has grown by 19%. This would have been higher as we did not receive some export orders due to the geopolitical tensions.

Future Growth Strategy

To continue our growth journey and to ward off seasonal spikes in coming years, we are putting following efforts:

- **Marketing:** Participating in multiple international events such as ADLM, USA (28th – 30th Jul'26) to capture more of the USA and LATAM markets. We are participating at WHX Johannesburg, South Africa (06th – 08th Oct'26). We are also actively exploring other such events in various markets.
- **Team:** We are strengthening our marketing team and expanding our distributor network across new markets to enhance our reach and customer engagement.
- **Regulatory:** As regulatory is the most important pillar of the IVD industry, we have been very compliant with largest CE-IVD and CDSCO range of products. In compliance with the new IVDR regulations, we are pleased to update that we have **passed the IVDR QMS audit** and all the necessary provisions are being complied to finally get the certification in due course of time.
- **Newer Product segment:** We are also trying to develop OEM a "Sample to Answer" system which will help us in entering into a different market segment. Additionally, we have developed Lyophilised products and we are doing final validation. Once completed, this will offer another stream of revenue. Although, it will not be very big in percentage terms, but it will help in maintaining the projected growth.
- **R&D:** As can be seen from our product range currently, that we have the largest product offering in the Industry, to continue this we are adding more products every year, however due to confidentiality reasons, we don't disclose our R&D pipeline.

TRUPCR®

TRUPCR® EUROPE

Sales Model – MDx (Q1 2026-27 – 3B India)

The company operates through three primary sales models in India:

- **Tender Sales:** This accounts for approximately 5% - 7% of the total sales and it depends on type of tender, etc.

- **Contractual / Reagent Rental Model:** In this model, we provide molecular diagnostic equipment like Real-Time PCR Systems or Automated / Manual Extraction Systems to the labs / hospitals with a condition that only our assays are used, these are long-term contracts which are projected to contribute business of 20%-25% for this financial year and coming years.

- **Other Supplies:** Apart from above, we sell products to hospitals and labs which comprises the remaining 65%-70% of the total sales.

Liberal Credit Policy

To increase sales and to sustain competition, we are following a liberal credit policy so that the customer is not lost to the competitors due to rigid payment terms (as post COVID there are lot of new diagnostic companies which offer stiff competition). This results in higher debtor level currently which we will gradually bring down in the coming years.

Our Footprints in India

Head Office & Manufacturing Site

Corporate Office – Delhi

Sales Office - Mumbai

Sales & Marketing Team

Distributor Network

Our Global Presence

We have widespread acceptance globally with our presence now in over **70 countries** spanning across **Europe, Middle East, APAC, LATAM, and North America (including the United States and Canada).** Now we are expanding in **Africa** through strategic partnerships with channel partners.

Business Outlook – International

- **Global Expansion:** Appointed new channel partners to strengthen international presence.
- **Territorial Growth:** Added customers in existing and new markets across Europe, Africa, and APAC.
- **Regulatory Progress:** Completed product registrations in several countries; ongoing in others to meet local regulations.
- **Tender Success:** Secured annual rate contracts in the Middle East, Southeast Asia, and Europe.
- **Distributor Engagement:** In advanced talks with leading international distributors for new projects.
- **Middle East Momentum:** Strong order inflow reflects growing market traction.
- **Targeted Market Entry:** Focused marketing driving entry into untapped markets.
- **Future Partnerships:** Exploring strategic alliances in Africa, LATAM, APAC, and Middle East.
- **Marketing Initiatives:** Participating in global events showcasing TRUPCR® strength and increasing visibility to support demand generation in priority markets.

TRUPCR®

TRUPCR® EUROPE

Exports – Past Trend & Near-Term Vision

Our exports have grown substantially over the past few years. We recorded a growth in exports of 38% for Q1 2026/27 versus Q1 2025/26. This growth would have been slightly higher, had there been favorable conditions due to the ongoing geo political tensions. Some orders have been delayed / cancelled and the logistics has also been challenging resulting in delays in supplies as well.

We now have presence across 70+ countries & 200+ customers. We have added a few countries post registration and tendering process. To increase growth, we are entering newer territories, where registrations take time of approximately 10–15 months post initiation. We have initiated registrations in a few countries in LATAM and South East Asia and we expect to start receiving commercial orders from these in the near future.



TRUPCR® Europe Limited - Manchester Site

In Q1 2026-27, TRUPCR® Europe Limited (TPE) has recorded a growth of 13% in Sales as shown below versus Q1 2025-26. TRUPCR® Europe Limited continues to be a strong growth driver for the group with its "Made in UK" portfolio gaining steady acceptance across Europe. The geopolitical tensions have resulted in a few orders which were not received. Had the situation been favorable, this growth would have been higher by 4-5%.

GBP 380,477
Q1 2025-26

GBP 432,997
Q1 2026-27

Backed by EU-aligned branding and smoother logistics, TPE is not only deepening its European footprint but also entering new geographies in LATAM, Africa and other priority markets. The site's ISO 13485:2016 certification from BSI (UK) further underlines our commitment to quality and regulatory compliance, enabling faster market access and building customer confidence. Ongoing marketing initiatives such as participation in global exhibitions (including ADLM in USA), onboarding of new distributors, and expansion of the marketing team, will further accelerate the proposed growth.

TRUPCR® EUROPE

Events & Conferences – ADLM 2026

Our strong international presence is reinforced through active participation in global conferences, where we showcase our products and introduce new verticals. These events are key to engaging stakeholders, building partnerships, and expanding global awareness.

Our participation in **ADLM 2026 (28th – 30th July, Anaheim),** alongside Coris BioConcept held promising discussions with prospective partners from new markets and strengthened relationships with existing distributors. We expect to see tangible financial outcomes from this event within the current fiscal year.

Events & Conferences - International

We continue to strengthen our global outreach and brand visibility through participation in leading international diagnostic platforms, including WHX Expo 2026 in Johannesburg. These strategic engagements provide opportunities to showcase the Company’s expanding molecular diagnostics portfolio, strengthen relationships with global distributors and healthcare stakeholders, and explore new market expansion and collaboration opportunities, supporting the Company’s long-term international growth strategy.

PERFORMANCE REVIEW

- As we had completed the acquisition of Coris on 29th August 2025 and according to the Ind AS rules, we can only consolidate from the date of acquisition. Therefore, this is the first year for Q1 numbers being consolidated versus previous year (not consolidated).
- Coris has received confirmation for HAT order for **EUR 1.41M** recently, to be supplied in Q3 i.e. December 2026. In 2025, HAT sales were **EUR 1.35M** which were also supplied in December 2025.
- HAT (Test for a parasite that causes African sleeping sickness) Contract is a Belgium Govt. Order of EUR 6.0M received in February 2024 to be supplied in 4 years.
- Coris closed revenue from operations at **EUR 796K** with an EBITDA loss of **EUR 325K** in Q1 2026/27 compared to revenue from operations at **EUR 788K** with an EBITDA loss of **EUR 414K** in Q1 2025/26. Due to control measures initiated, the loss has been reduced by **21%** and in coming years these efforts will yield better results to increase company's profitability. As a historical trend, Q1 and Q2 for Coris is loss making and Q3 and Q4 are profitable due to above HAT order supply. The main reason for EBITDA loss is a high R&D team cost which will eventually help in launching new products in the coming years.
- When comparing Q1 2026/27 versus Q1 2025/26 -
  - There is growth of 12% in AMR which consists of 70% of the sales in Q1 2026/27.
  - There is a de-growth of 54% in other categories which consists of 30% of the remaining sales because of Chinese competition.

FUTURE OUTLOOK

- We expect AMR products to grow at 15-20% for 2026-27 and the other products to de-grow due to Chinese competition. Overall, in 2026-27, we expect the sales to grow at 10-15% with slight positive EBITDA. Although, the geo-political situation is affecting sales, we still expect to achieve the targeted growth.
- Coris has started working on getting US FDA registration for RESIST-5 AMR, which will take 1-2 years for completion. Once completed, this will be a key growth driver for Coris' sales.
- Coris has been granted the IVDR certification for its two main AMR products. This is a big milestone as IVDR certification will help in growing the market.
- They have a strong R&D team and have developed new products which will be launched in the coming years, this should help in increasing sales.
- The US FDA will open a big US market opportunity which should start sales in 2027-28, and will also help in tapping into other markets which recognize FDA.
- Coris is synonymous to AMR in the global market and a respected European brand with IVDR certification and FDA, it should be able to grow its product range in a positive way in the existing and newer markets.
- Now with increased marketing efforts in Middle East, APAC and US, this will also help in achieving better revenue.

EU IVDR Certification

On track towards IVDR certification of our product portfolio

- Regulation (EU) 2017/746 on *in vitro* diagnostic medical devices (IVDR) was published on 5 April 2017, repealing Directive 98/79/EC and introducing a strengthened regulatory framework applicable from 26 May 2026.
- 3B BlackBio Dx Limited is progressing steadily on its IVDR transition plan to ensure compliance of key TRUPCR® kits with Regulation (EU) 2017/746, and 3B can continue to sell its products till 31st December 2028 (transition period) as legacy devices and before this the IVDR certifications would have been received.
- BSI Group has been appointed as the Notified Body for conformity assessment under IVDR and agreement duly signed with them.
- Our regulatory team along with multiple departments is working on the implementation of the IVDR requirements.
- The Company has successfully passed its IVDR-aligned QMS audits conducted by BSI Group in November 2025 and further technical evaluation of product groups is underway.

Our Certifications

bsi.

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

3B BlackBio Dx Limited
7-C, Industrial Area
Govindpura
Bhopal
Madhya Pradesh
462 023
India

Holds Certificate Number: MD 813787

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Design, Development, Manufacturing, Sales & Distribution of PCR, Rapid & ELISA In-Vitro Diagnostic Test Kits for use in Oncology, Genetics, Infectious, Blood-Borne & Vector-Borne Diseases.

For and on behalf of BSI:

Graeme Tunbridge, Senior Vice President Global Regulatory & Quality

Original Registration Date: 2024-10-23
Latest Revision Date: 2025-01-23

Effective Date: 2025-02-02
Expiry Date: 2028-02-01

Page: 1 of 2

...making excellence a habit.™

ISO 13485:2016

ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI

IVD

Licensed by CDSCO

Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India

CE IVD

Over 40 key assays are CE-IVD marked post new IVDR regulations

TRUPCR®

TRUPCR® EUROPE

What Sets us Apart

- Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available
- Large, expansive and highly loyal customer base spread across government & private hospitals and labs in over 70+ countries
- Well experienced, strong and well retained R&D team
- Widest as well as most unique range of molecular diagnostic kits available anywhere globally
- The only Indian Company to have a subsidiary in UK, establishing our credibility globally
- Both India and UK Sites are ISO 13485 certified by BSI, UK
- Only Indian company to get US FDA (EUA) for COVID in 2020
- Quickest and most reliable large scale production capacity in the entire nation
- Only molecular company globally to integrate offerings for Rapid Diagnostics (Lateral Flow) & NGS solutions and covering the entire range of molecular diagnostic solutions in its true sense

TRUPCR®

TRUPCR® EUROPE

Our R&D Strengths

- Our well retained **R&D team of scientific professionals including Ph.Ds. and M.Scs.** brings vast experience in molecular diagnostics, assay design, and bioinformatics which reflects a stable, motivated workforce committed to scientific excellence and long-term innovation.

- This is evident from our wide product range spanning across **qPCR, Lateral Flow, and NGS assays**, addressing infectious diseases, oncology, genetic disorders, and AMR.

- Our R&D doesn't stop at development only. We continuously improve our assay sensitivity, specificity, and workflow efficiency based on the performance data.

- Our flexible R&D framework allows us to respond rapidly to new health threats, such as pandemics like COVID-19 or antimicrobial resistance (with our Rapid Tests for AMR), with quick-to-deploy diagnostic assays.

Due to competition, we are not disclosing our exact R&D pipeline, however, there are several products in pipeline for the coming 2 years. We would like to reiterate that R&D remains central to our long-term strategy enabling **continuous pipeline expansion, faster go-to-market**, and market leadership in molecular diagnostics.

TRUPCR®

TRUPCR® EUROPE

Comprehensive Panels for Syndromic Testing

The COVID-19 pandemic has underscored the importance of multiplex PCR assays and syndromic diagnostic testing for infectious diseases, highlighting their utility in rapidly diagnosing and managing contagious illnesses. Syndromic testing, which combines multiple pathogen tests into a single panel targeting specific syndromes, has emerged as a valuable tool in combating the spread of infectious diseases like COVID-19.

By detecting multiple pathogens simultaneously within a short timeframe, syndromic testing reduces the time required to provide a diagnosis. This expeditious diagnosis enables healthcare professionals to make informed therapeutic decisions earlier in the course of the disease, potentially leading to more precise treatment interventions and improved patient outcomes.

TRUPCR® has the widest range of comprehensive panels which demonstrates our commitment to meeting the diverse needs of clinicians across various healthcare settings. Whether it's respiratory, gastrointestinal, or other infectious disease syndromes, offering tailored panels ensures that clinicians have access to the necessary diagnostic tools to effectively evaluate and manage their patients.

TRUPCR® Flu Panel with RSV Detection Kit

TRUPCR® Respiratory Pathogen Panel Kit

TRUPCR® STD Panel Kit

TRUPCR® TORCH Panel Kit

TRUPCR® Tropical Fever Panel Kit

TRUPCR® UTI ID Panel Kit

TRUPCR®

TRUPCR® EUROPE

Antimicrobial Resistance – A Silent Pandemic

Antimicrobial resistance (AMR) has become one of the most significant threats to public health worldwide, often referred to as the **"silent pandemic"** due to its gradual and insidious nature.



Image Source: AMR Action Fund

- Encouraging judicious use of antibiotics through antibiotic stewardship programs can help mitigate the development and spread of antimicrobial resistance.
- Implementing effective infection prevention and control measures in healthcare settings can help reduce the spread of resistant pathogens.
- Increasing public awareness about antimicrobial resistance and its implications for public health is crucial for fostering behavior change and garnering support for AMR initiatives.
- Increased diagnostic screening to identify the specific pathogens causing an infection and determine their susceptibility to antibiotics.

TRUPCR®

TRUPCR® EUROPE

Solutions by 3B - to combat Antimicrobial Resistance

We offer an extensive range of RT-PCR-based and lateral flow assays that demonstrates our proactive approach to addressing the global concern of antimicrobial resistance (AMR).

TRUPCR® have both singlex and multiplexing RT-PCR assays for the detection & differentiation of multiple targets responsible for AMR. RT-PCR-based assays are highly sensitive and specific tools for detecting targets associated with antimicrobial resistance genes or markers. These assays enable the rapid identification of resistant pathogens, allowing healthcare providers to prescribe appropriate antimicrobial therapies and implement infection control measures more effectively.

TRUPCR® AST Panel Kit

TRUPCR® UTI AST Panel Kit

TRUPCR® Carbapenem Resistance Detection Kit

TRUPCR® MRSA Detection Kit

TRUPCR® VRE Detection Kit

TRUPCR® Rifampicin & Isoniazid Resistant MTB Detection Kit

TRUPCR®

TRUPCR® EUROPE

Solutions by 3B - to combat Antimicrobial Resistance

We are pleased to inform that we have successfully completed the collaborative R&D of the Rapid Tests for Anti-Microbial Resistance (AMR). The below assays have been launched to cater to the AMR segment:

- TRURAPID® RESIST-5 OKNVI Rapid Test (For Resistance in Carbapenems)
- TRURAPID® RESIST ACINETO Rapid Test (For Resistance in Carbapenems in *Acinetobacter* spp.)
- TRURAPID® RESIST CTX-M Rapid Test (For Resistance in Cephalosporins)

- TRURAPID® RESIST 5 OKNVI Rapid Test has been sampled in multiple labs and leading hospitals across India and we have started receiving orders as well from some well-established labs as well.
- This product is used for deciding the patient treatment regimen for the carbapenem antibiotics - imipenem, meropenem, ertapenem and doripenem which are very important for patient management.
- The benefits of this test is that we can get the result regarding the antimicrobial resistance (AMR) status within 15 minutes of the positive culture or positive blood culture saving the most crucial time for deciding treatment regimen.

TRURAPID®

Fungal Pathogens – The Overlooked Threat

Invasive and superficial fungal infections are an increasingly recognized global health burden, fueled by growing immunocompromised populations, rising antifungal resistance, and persistent diagnostic delays from slow, low-sensitivity culture methods.

Fungal pathogens are frequently underappreciated relative to bacterial and viral agents, yet they represent a major and growing source of both community-acquired and hospital-associated disease. Their relevance stems from three converging trends: an expanding population of immunocompromised patients (transplant recipients, oncology patients, ICU patients, and those with diabetes or HIV), the emergence of antifungal resistance across multiple genera, and the inherent limitations of conventional diagnosis, where slow-growing cultures and low sensitivity routinely delay identification and appropriate treatment. Accurate, species-level detection is clinically important because treatment, prognosis, and containment strategies differ substantially even within the same genus.

6.5 MILLION
People affected by invasive fungal infections every year

3.8 MILLION
Deaths linked to fungal disease each year

19
Fungal pathogens on the WHO Priority Pathogens List (2022)

Source: Denning D. Global incidence and mortality of severe fungal disease, Lancet Infect Dis 2024; WHO Fungal Priority Pathogens List, 2022

TRUPCR®

TRUPCR® EUROPE

Newly Launched Solutions by 3B - to combat Fungal Pathogens

TRUPCR® Skin and Nail Fungus Panel Kit

(Real-Time PCR assay for qualitative detection of fungal DNA associated with skin and nail infections)

TRUPCR® Aspergillus Detection & Differentiation Kit

(Real-Time PCR based detection of Aspergillus DNA)

TRUPCR®

TRUPCR® EUROPE

Next-Gen Sequencing (NGS) Vertical

We have started getting some traction for the TRUNGS® assays from the customers however, it is very low. The NGS market is at a very nascent stage and is divided in Whole Genome Sequencing, Whole Exome Sequencing, NIPT etc.

With the TRUNGS® vertical, our main intent was to be technologically relevant so that we can offer all the molecular diagnostics solutions to our customers under one roof. Now we have a good grip of the NGS assays, however, commercialization is challenging as the field is highly competitive and labs try to make their own kits (homebrew) which is an old methodology and used in PCR as well. TRUNGS® is focussed on very niche products in this segment, hence, we do not expect major high growth / revenue from NGS immediately, however, it will be gradual.

Last year, we had launched the **"TRUNGS® Solid Tumor Panel"** for detection genes associated with solid tumors such as lung, gastro-intestinal/colorectal, breast, liver and ovarian tumors.

Now, after extensive R&D efforts we will be launching below products commercially:

- **BRCA Plus Kit –** For detection of germline / somatic mutations associated with breast, ovarian and prostate. cancers.
- **MTB - MDR NGS Kit –** Advanced Genomic Profiling of TB Drug Resistance Using Targeted Sequencing

truNGS®

Digital PCR

Our Research and Development (R&D) team is committed to the ongoing development of innovative products leveraging cutting-edge technologies. Through our dedication to scientific advancement and technological innovation, we strive to address emerging challenges and meet the evolving needs of our customers and stakeholders.

Through our relentless pursuit of excellence, we endeavor to bring to market new products that not only meet but exceed industry standards for quality, performance, and reliability.

Continuing our journey for R&D, our team has been working on the development of assays based on Digital PCR (dPCR) technology which enables absolute quantification of target nucleic acids. The products under this segment have been commercially launched in Q3 of FY 2025-26, although it is in very initial stage and sale is nominal.

By leveraging the capabilities of dPCR technology, our R&D team has the opportunity to develop innovative assays that address key challenges in healthcare & biotechnology. This could lead to the development of valuable diagnostic tools with significant impact on disease detection, treatment monitoring, and research advancements.

TRUdPCR

Automated Extraction System



We are trying to offer automated extraction systems to our customers. Our team alongwith VGT's team has invested considerable time and effort into identifying an automated extraction system that meets the growing needs of our customers. With this new addition, we are confident that we can provide even greater value and help our customers stay ahead in an increasingly competitive landscape. To support this, we will provide end-to-end onboarding—installation, application training, and responsive after-sales service—so labs can adopt the platform quickly and run it reliably.

We are planning to supply these instruments to our customers who have long-term contracts on a reagent – rental basis with us so these customers can be retained for a longer duration. This approach keeps upfront costs low, offers predictable operating expenses, and secures priority access to reagents and consumables.

TRUPCR®

TRUPCR® EUROPE

Long Term Contracts

Signing long-term contracts with large customers is a strategic move that provides stability and predictability to the business operations. By securing commitments for 2-3 years, we can better forecast revenue streams and plan resources accordingly, reducing uncertainty and mitigating risks associated with fluctuating market conditions.

Considering the same, we have over 15 contracts already in place (under Reagent-Rental Model) that demonstrates the confidence and trust that customers have in our products and services. From these contracts, we project a steady business of 20%-25% of the total revenue.

We foresee the below benefits from this business model:

- Steady Revenue Stream
- Enhanced Customer Relationships
- Increased Market Penetration
- Competitive Advantage over peers
- Opportunities for Upselling
- Long-Term Partnerships from new accounts

TRUPCR®

TRUPCR® EUROPE

Utilization of Funds

During the last 2 years, we have evaluated several companies in the IVD space, however, the valuations were high due to demand from diagnostic companies based on Covid profits. Also, the Sales & EBITDA were not matching our IRR or future growth possibility, hence we did not proceed.

However, now with acquisition of Coris BioConcept SRL, Belgium, we have been able to do the first acquisition after a long search & negotiation which will strengthen our credibility in the market as a genuine buyer.

We are actively looking for M&A opportunities across globe preferably in the EU and the USA. We are looking for manufacturers or distributors in the IVD segment which can include molecular, microbiology, immunology and similar segment.

Existing & Utilized Capacity

The company is currently operating at ~65% of its installed capacity, with full potential achievable during seasonal demand spikes such as vector-borne disease outbreaks and flu season. During lean season periods, capacity utilization remains around ~50%, ensuring flexibility to scale production rapidly in response to market needs.

TRUPCR®

TRUPCR® EUROPE

3B for CSR

Army Wives Welfare Association or AWWA for short is an association that works for the welfare of the spouses, children and dependents of Army personnel. The aim of AWWA therefore is to support and augment the official welfare efforts within the Indian Army, focusing primarily on the wel--fare of families, children and widows of all ranks including those of retired personnel of the Army. **We feel immensely proud to inform that your company "3B" through different projects under AWWA has been supporting families of the martyrs who sacrificed their lives in the line of duty.**

ARUSHI is a Bhopal based not-for-profit organization working with and for people with disabilities and issues related to them. The basic objective of ARUSHI's work is to generate opportunities and develop capacities in people with disabilities. **"3B" collaborated with ARUSHI to upgrade their upgrading its' Occupational Therapy Centre for children with special abilities.** The main objective of this project is to upgrade the occupational therapy department with best equipment and variety of activities for children with Autism, ADHD & Children with Delayed Development.

3B for CSR

Sightsavers India

Sightsavers is an international organisation that works in more than 30 countries to eliminate avoidable blindness, and fight for the rights & needs of people with disability. Sightsavers' work in India has enabled thousands of people to lead lives of independence and dignity.

"3B" has been collaborating with Sightsavers for over 3 years to provide support for their project "Netra Vasant" - Rural Eye Health Programme" in various districts of Madhya Pradesh. The scope of work is to identify patients with cataract in the selected blocks and conduct eye screening services. Our contribution has enabled Sightsavers to extend their reach to the poor, especially the marginalized / underserved population in districts of Madhya Pradesh. Under this initiative, Sightsavers has conducted over 50 camps across the region benefitting more than 4000 people by providing them with eye screenings and referring them to treatments accordingly.

Friends of Tribals Society

Friends of Tribals Society (FTS) established on January 15, 1989 is a non-profit organisation dedicated to the upliftment of tribals. FTS runs One Teacher School (OTS) or Ekal Vidyalaya, which imparts non- formal primary education to children between 6 and 14 years of age.

3B BlackBio is supporting the FTS to set up "Ekal Vidyalaya" in the villages in Tribal areas of Raisen, Bareli and Betul districts of Madhya Pradesh.

TRUPCR®

TRUPCR® EUROPE

3B for CSR

Prerna Sewa Trust, Bhopal, has been serving poor patients at Hamidia Hospital, Bhopal for decades through daily meals, free medicines, medical equipment, and support for treatment of serious ailments. In line with our CSR commitment, 3B has been supporting the Trust by funding medical aid, medical equipment such as stretchers and wheelchairs, and food packets for the underprivileged alongwith any necessary items needed by the trust to support the patients and their families at the hospital.

Sahara Saksharta is a social initiative dedicated to promoting education and literacy among underprivileged communities in Bhopal, Madhya Pradesh. The organisation works towards empowering individuals through educational support, skill development, and awareness programmes that help build self-reliance and social inclusion. As part of our CSR commitment, we are pleased to support their efforts in fostering education, creating opportunities for learning, and contributing to sustainable community development.

3B for CSR

Cachar Cancer Hospital & Research Centre is committed to providing affordable and accessible cancer care to patients across Northeast India, particularly serving economically disadvantaged communities. The centre has received national and international recognition for its impactful work, driven by the dedicated leadership of Dr. Ravi Kannan, whose patient-centric approach, emphasis on community outreach, and focus on holistic cancer care have significantly strengthened oncology services in the region. Through early detection programmes, treatment support, and patient welfare initiatives, the institution continues to transform lives. As part of our CSR commitment, we are proud to support the hospital in its mission to expand access to quality cancer care and bring hope to patients and their families.

3B's CSR Policy

- **Health –** We believe that healthcare shouldn't be a privilege but the right of every individual.
- **Education & Employment –** We follow the saying "Give a man a fish and you feed him for a day, but teach a man to fish and you feed him for a lifetime."
- **Community Responsibility –** We believe every community has work to be done, and it begins with those closest to us.

Recognitions & Awards

Received the **"Outstanding Achievement Award"** in recognition of excellence in R&D through technology by FMPCCI, Bhopal, during the 4th Outstanding Achievement Award 2016 by Hon'ble Chief Minister of Madhya Pradesh, held on 12th Aug. 2017

Received the **"National MSME Award – 2018"** by Hon'ble President of India on 11th May 2018 under MSME category for the successful commercialization of a technology based product

Received the **"Outstanding Achievement Award"** in recognition of excellence in R&D and Innovative Products Category during the 6th Outstanding Achievement Award 2022 by Hon'ble Governor of Madhya Pradesh, held on 10th April 2022

JAI HIND

3B BlackBio Dx Ltd.